Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Prevalence of EED and Quality of Life Evaluated by Gastroesophageal Reflux Disease (GERD)-Q in Korean GERD Patients (Preedom)

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00768196
First received: October 1, 2008
Last updated: December 6, 2010
Last verified: December 2010

October 1, 2008
December 6, 2010
September 2008
Not Provided
The primary variable is the total rate of GERD patients who had EED symptom and effect on their quality of life.
Same as current
Complete list of historical versions of study NCT00768196 on ClinicalTrials.gov Archive Site
The secondary variable is the comparison of the EED symptom frequency in ERD and NERD patients.
Same as current
Not Provided
Not Provided
 
Prevalence of EED and Quality of Life Evaluated by Gastroesophageal Reflux Disease (GERD)-Q in Korean GERD Patients
Prevalence of EED and Quality of Life Evaluated by Gastroesophageal Reflux Disease (GERD)-Q in Korean GERD Patients

The purpose of this study is to asses the EED symptom prevalence in Koran GERD patients with typical reflux symptom and to evaluate quality of life with the scales including Gerd Q.

Not Provided
Observational
Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample

general hospital sample

Gastroesophageal Reflux Disease
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
2000
February 2009
Not Provided

Inclusion Criteria:

  • GERD patients who have experienced heartburn or acid regurgitation during past 7 days
  • GERD patients who have already undergone endoscopy before enrolment

Exclusion Criteria:

  • Involvement in the planning and conduct of the programme
  • The person who took the medicine such as PPI or H2RA during the last 7 days
  • Severe systemic disease
Both
20 Years to 80 Years
No
Contact information is only displayed when the study is recruiting subjects
Korea, Republic of
 
NCT00768196
NIS-GKR-DUM-2008/1
No
Not Provided
AstraZeneca
Not Provided
Study Director: Joon-Woo Bahn AstraZeneca Korea
AstraZeneca
December 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP